Enhancement of CD117-targeted bispecific T-cell engagement by CD33-targeted bispecific T-cell co-stimulation in acute myeloid leukemia - PubMed
4 hours ago
- #bispecific antibodies
- #T-cell engagement
- #acute myeloid leukemia
- The study addresses challenges in T-cell engaging bispecific antibodies (TCEs) for acute myeloid leukemia (AML), including lack of tumor-selective targets and insufficient T-cell activation.
- A CD33xCD28 IgG4-scFv2 antibody was created to provide CD28 co-stimulation and tested in combination with a CD117xCD3 TCE.
- The combination enhanced T-cell mediated lysis of AML cells by improving T-cell activation, proliferation, cytokine release, attachment speed, and lytic events.
- This approach also increased specificity towards AML cells expressing both CD117 and CD33 targets, potentially reducing off-target effects.